- Home
- KLRS vs XPL Comparison
KLRS vs XPL Comparison
Compare KLRS & XPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KLRS
- XPL
- Stock Information
- Founded
- KLRS 2019
- XPL 1984
- Country
- KLRS United States
- XPL United States
- Employees
- KLRS N/A
- XPL N/A
- Industry
- KLRS Biotechnology: Biological Products (No Diagnostic Substances)
- XPL Precious Metals
- Sector
- KLRS Health Care
- XPL Basic Materials
- Exchange
- KLRS Nasdaq
- XPL Nasdaq
- Market Cap
- KLRS 46.0M
- XPL 47.9M
- IPO Year
- KLRS N/A
- XPL N/A
- Fundamental
- Price
- KLRS $3.71
- XPL $0.72
- Analyst Decision
- KLRS Strong Buy
- XPL Strong Buy
- Analyst Count
- KLRS 2
- XPL 2
- Target Price
- KLRS $23.00
- XPL $1.20
- AVG Volume (30 Days)
- KLRS 689.3K
- XPL 176.0K
- Earning Date
- KLRS 11-15-2025
- XPL 11-04-2025
- Dividend Yield
- KLRS N/A
- XPL N/A
- EPS Growth
- KLRS N/A
- XPL N/A
- EPS
- KLRS N/A
- XPL N/A
- Revenue
- KLRS N/A
- XPL N/A
- Revenue This Year
- KLRS N/A
- XPL N/A
- Revenue Next Year
- KLRS N/A
- XPL N/A
- P/E Ratio
- KLRS N/A
- XPL N/A
- Revenue Growth
- KLRS N/A
- XPL N/A
- 52 Week Low
- KLRS $2.14
- XPL $0.54
- 52 Week High
- KLRS $24.15
- XPL $0.90
- Technical
- Relative Strength Index (RSI)
- KLRS 52.79
- XPL 40.29
- Support Level
- KLRS $2.37
- XPL $0.76
- Resistance Level
- KLRS $4.90
- XPL $0.90
- Average True Range (ATR)
- KLRS 0.70
- XPL 0.05
- MACD
- KLRS -0.02
- XPL -0.01
- Stochastic Oscillator
- KLRS 24.95
- XPL 16.82
About KLRS Kalaris Therapeutics Inc. Common Stock
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.
About XPL Solitario Resources Corp.
Solitario Resources Corp is exploration company engaging in acquiring, exploring, and developing zinc properties and other precious metals in safe jurisdictions in North and South America. It has joint venture interests in large, high-grade zinc development projects. The Florida Canyon Zinc Project in Peru is a development asset held jointly with Nexa Resources S.A., Golden Crest Project in South Dakota and the Lik Zinc Project represents a large-tonnage, high-grade development project in Alaska in partnership with Teck Resources. In addition, the company has an additional portfolio of exploration properties and royalties in the Americas.